# ProThera Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prothera-biologics

- Industry: Biotechnology
- Headquarters: East Providence, US
- Website: www.protherabiologics.com
- Total disclosed funding: $0.8M
- Latest round: Series A (Sep 5, 2012)
- Investors on record: 1

## About

ProThera Biologics Inc. specializes in developing innovative therapeutic solutions for severe inflammatory diseases using Inter-alpha inhibitor proteins to modulate immune responses, aiming to improve patient health outcomes in critical care settings.Founded in 2001, ProThera Biologics Inc., headquartered in East Providence, US, focuses on therapeutic solutions for severe inflammatory conditions. The company has undergone no major pivots in its business strategy and operates independently. Its founder's background details are not publicly available. ProThera has engaged in 6 investment rounds with the most recent funding being a Grant of USD 1.95 mn received on June 26, 2017, making it the total amount raised.ProThera Biologics focuses on developing innovative therapeutic solutions for severe inflammatory diseases through a specialized class of human plasma proteins known as Inter-alpha inhibitor proteins (IAIP). These proteins play a critical role in controlling inflammation by modulating various immune pathways, which is paramount in addressing life-threatening immune responses that often lead to high mortality rates in affected patients. By harnessing the natural anti-inflammatory properties of IAIP, ProThera aims to restore immune regulation and improve patient health outcomes, particularly for those who are admitted to Intensive Care Units and face significant health risks due to uncontrolled inflammation. The company’s target market includes hospitals and healthcare providers in North America and Europe, where the demand for effective treatments for severe inflammatory conditions is especially pronounced.ProThera Biologics generates revenue primarily through partnerships with healthcare institutions and pharmaceutical companies that seek to utilize its innovative IAIP-based therapies. The company's business model involves B2B transactions, where it collaborates with hospitals and clinics to provide its life-saving medications. By engaging in agreements for the supply of IAIP therapies, ProThera establishes pricing structures based on the specific treatment regimens required by patients. The financial transactions are structured to accommodate the needs of healthcare providers, potentially involving per-treatment fees or volume-based pricing that reflect the scale of usage within healthcare settings. The flagship IAIP therapies are positioned as essential interventions for managing severe inflammation, catering specifically to the healthcare market that prioritizes advanced therapeutic options for high-risk patients.ProThera Biologics is focused on expanding its product pipeline with new therapies designed to enhance the treatment of severe inflammatory diseases. Following the receipt of USD 1.95 mn in Grant funding from the National Institutes of Health on June 26, 2017, the company plans to utilize these funds to support research and development efforts aimed at launching additional IAIP-based treatments within the next few years. Furthermore, ProThera aims to extend its market reach into Europe and Asia, targeting healthcare providers that require advanced therapeutic solutions for critical care patients.

## Funding rounds

- Series A, Sep 5, 2012, $0.3M — Slater Technology Fund
- Seed, Jun 24, 2008, $0.3M — Slater Technology Fund
- Series A, Jun 24, 2008, $0.3M — Slater Technology Fund

## Investors

- Slater Technology Fund (https://capitalatlas.ai/funds/slater-technology-fund) — Seed, Series A